liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
The whole story: Treatment outcomes with Symbicort®
Linköping University, Faculty of Health Sciences. Linköping University, Department of Clinical and Experimental Medicine, Allergy Centre . Linköping University, Department of Clinical and Experimental Medicine, Allergy Centre .
Mainz University Hospital, Mainz, Germany.
Ullevål Hospital, Oslo, Norway.
Clinical Science, AstraZeneca R and D, Lund, Sweden.
2002 (English)In: Respiratory Medicine, ISSN 0954-6111, Vol. 96, no SUPPL. 1Article, review/survey (Refereed) Published
Abstract [en]

Asthma is a chronic inflammatory disorder of the airways that has a considerable socioeconomic impact. Asthma management guidelines have been introduced to help provide better long-term control of asthma. Although recommended guidelines may increase the direct medication costs, the overall direct costs of asthma may be reduced due to fewer exacerbations. In addition, indirect costs due to lost productivity and mortality are reduced and patients have an improved quality of life. Inhaled corticosteroids are first-line therapy in the treatment of persistent asthma. Against this background, we have assessed the cost-effectiveness of Symbicort® (budesonide and formoterol in a single inhaler), a treatment that provides better control of asthma compared with budesonide alone. While the prescribing costs of Symbicort® were found to be higher than for budesonide alone, these were partially offset by reduced costs due to fewer asthma exacerbations and a reduced need for other medications. Combined long-term therapy with budesonide and formoterol also improves patient quality of life compared with budesonide alone. Two other factors associated with asthma treatment success and cost-effectiveness are patient/physician education and good patient adherence to prescribed therapy. The introduction of a single inhaler that is easy to use in simple treatment regimens may improve patient adherence to prescribed medication, thus resulting in improved asthma control and fewer exacerbations. Treatment with Symbicort® is more cost-effective than treatment with budesonide alone. © 2002 Elsevier Science Ltd.

Place, publisher, year, edition, pages
2002. Vol. 96, no SUPPL. 1
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-47108DOI: 10.1016/S0954-6111(02)90080-6OAI: diva2:268004
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2011-01-13

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Zetterström, Olle
By organisation
Faculty of Health SciencesAllergy Centre
In the same journal
Respiratory Medicine
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 11 hits
ReferencesLink to record
Permanent link

Direct link